The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden et al. · Arthritis & Rheumatism · 1998 · 1.6K citations

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Mark C. Genovese, Jean‐Claude Becker, Michael Schiff et al. · New England Journal of Medicine · 2005 · 1.2K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Daniel E. Fürst, Edward Keystone, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2011 · 692 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

G. M. Bartelds, Carla A. Wijbrandts, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2007 · 567 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17